Analysts Set Silence Therapeutics plc (NASDAQ:SLN) PT at $54.75

Silence Therapeutics plc (NASDAQ:SLN) has received an average recommendation of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $54.75.

Several analysts have issued reports on SLN shares. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. BMO Capital Markets reiterated an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. Chardan Capital reissued a “buy” rating and issued a $55.00 target price on shares of Silence Therapeutics in a report on Tuesday, December 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a report on Wednesday, January 29th.

Silence Therapeutics Price Performance

NASDAQ:SLN opened at $5.75 on Friday. Silence Therapeutics has a one year low of $4.82 and a one year high of $27.72. The business has a fifty day moving average price of $6.45 and a 200-day moving average price of $13.42. The firm has a market capitalization of $172.10 million, a price-to-earnings ratio of -3.66 and a beta of 1.05.

Institutional Trading of Silence Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC grew its position in Silence Therapeutics by 609.2% in the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock worth $42,000 after acquiring an additional 5,233 shares in the last quarter. Values First Advisors Inc. bought a new stake in shares of Silence Therapeutics in the 3rd quarter valued at approximately $56,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Silence Therapeutics in the 4th quarter worth approximately $69,000. FNY Investment Advisers LLC bought a new position in shares of Silence Therapeutics during the 4th quarter valued at approximately $120,000. Finally, Verition Fund Management LLC purchased a new stake in Silence Therapeutics during the 3rd quarter valued at $207,000. 98.73% of the stock is currently owned by institutional investors.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.